Oncopeptides publishes Q3 2021 report

Oncopeptides publishes Q3 2021 report

PR Newswire

STOCKHOLM, Nov. 24, 2021

Back to the future

STOCKHOLM, Nov. 24, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the third quarter 2021.

Financial overview July-September          

Financial overview January-September          

Significant events July-September          

Significant events after the reporting period           

Financial overview of the Group

                                   

(SEK thousand)

                                   

                                  

  2021 Jul-Sep

                                  

                                   

  2020 Jul-Sep

                                   

                                   

2021 Jan-Sep

                                   

                                   

2020 Jan-Sep

                                   

                                   

2020 Jan- Dec           

                                              

                                                                       

Net sales

                                   

 

54,276

 

 

-

 

 

140,005

 

 

-

 

 

-

 

                                    

Gross profit

                                   

 

22,683

 

 

-

 

 

105,262

 

 

-

 

 

-

 

                                   

Gross margin

                                   

 

42%

 

                                   

N/A

                                   

 

75%

 

                                   

N/A

                                   

 

N/A 

                                              

                                   

Operating loss

                                   

 

-338,913

 

 

-383,498

 

 

-1,031,081

 

 

-1,079,706

 

 

-1,591,279

 

                                   

Loss after tax

                                   

 

-777,547

 

 

-388,357

 

 

-1,036,327

 

 

-1,081,727

 

 

-1,594,693

 

                                   

Earnings per share before and after dilution (SEK)

                                   

 

-10,33

 

 

-5.71

 

 

-14,27

 

 

-17.87

 

 

-25.57

 

                                   

Cash flow from operating activities

                                   

 

-336,528

 

 

-340,841

 

 

-1,069,937

 

 

-939,347

 

 

-1,296,509

 

                                   

Cash and cash equivalents at the end of the period 

                                   

 

671,269

 

 

1,251,629

 

 

671,269

 

 

1,251,629

 

 

840,255

 

                                   

R & D costs/operating expenses, %

                                   

 

41%

 

 

50 %

 

 

44%

 

 

59 %

 

 

54 %

 



Conference call for investors, analysts and the media 
Investors, financial analysts, and media are invited to participate in a webcast with a QnA at 10:00 CET. The event will be hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation will be held in English.

The webcast will be streamed via this link which can also be found on the website: www.oncopeptides.com.


Phone numbers for participants from:
SE: +46 8 505 583 53
UK: +44 333 300 92 61
US: +1 833 823 05 89


For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28

Linda Holmström, Director of Investor Relations, Oncopeptides AB
E-mail: linda.holmstrom@oncopeptides.com  
Cell phone: +46 70 873 40 95


This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on November 24, 2021.

About Oncopeptides
Oncopeptides is a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from the PDC platform, Pepaxto® (INN melphalan flufenamide), also called melflufen was granted accelerated approval in the U.S., on February 26, 2021, in combination with dexamethasone, for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Oncopeptides voluntarily withdrew the drug from the U.S. market on October 22, 2021, due to worse overall survival data in the phase 3 OCEAN study. The study was a post-approval requirement under the accelerated approval program. Oncopeptides is developing several new compounds based on the PDC platform. The Corporate Headquarters is based in Stockholm, Sweden. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information about the company is available on www.oncopeptides.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oncopeptides-ab/r/oncopeptides-publishes-q3-2021-report,c3459305

The following files are available for download:

https://mb.cision.com/Main/15404/3459305/1500560.pdf

The full report (PDF)

https://mb.cision.com/Public/15404/3459305/9e58d785ab73358f.pdf

Press release (PDF)

 

Voltar noticias em Inglês